High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study

BACKGROUND AND OBJECTIVE: The results of the CheckMate 025 trial established the status of nivolumab in the second-line treatment of metastatic renal cell carcinoma (mRCC), with an objective response rate (ORR) of 25% and a complete response (CR) rate of 1%. Thus, the efficacy of anti-programmed dea...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Lingdi, Li, Tiepeng, Song, Yongping, Yang, Yonghao, Ma, Baozhen, Zhang, Yong, Shang, Yiman, Xu, Benling, Guo, Jindong, Qin, Peng, Han, Lu, Fu, Xiaomin, Lin, Hongwei, Liu, Liang, Ren, Xiubao, Wang, Zibing, Gao, Quanli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764153/
https://www.ncbi.nlm.nih.gov/pubmed/35058923
http://dx.doi.org/10.3389/fimmu.2021.779248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764153/
https://www.ncbi.nlm.nih.gov/pubmed/35058923
http://dx.doi.org/10.3389/fimmu.2021.779248

Ejemplares similares